Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) and Can-Fite BioPharma (NYSE:CANF – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
74.2% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 5.4% of Can-Fite BioPharma shares are held by institutional investors. 16.1% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for Foghorn Therapeutics and Can-Fite BioPharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Foghorn Therapeutics presently has a consensus target price of $27.67, suggesting a potential upside of 118.71%. Given Foghorn Therapeutics’ higher possible upside, equities analysts clearly believe Foghorn Therapeutics is more favorable than Can-Fite BioPharma.
Earnings & Valuation
This table compares Foghorn Therapeutics and Can-Fite BioPharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Foghorn Therapeutics||$1.32 million||395.39||-$101.32 million||($2.73)||-4.62|
|Can-Fite BioPharma||$850,000.00||30.24||-$12.61 million||($0.69)||-1.37|
Can-Fite BioPharma has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Foghorn Therapeutics has a beta of 3.35, indicating that its share price is 235% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.
This table compares Foghorn Therapeutics and Can-Fite BioPharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Foghorn Therapeutics beats Can-Fite BioPharma on 9 of the 13 factors compared between the two stocks.
About Foghorn Therapeutics (Get Rating)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Can-Fite BioPharma (Get Rating)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.